铁调素及相关干预药物的研究进展
Hepcidin regulation and related drugs
杨钧岚 1邢婕 1韦致远 1张晓良2
作者信息
- 1. 东南大学医学院(南京,210009)
- 2. 东南大学附属中大医院肾内科
- 折叠
摘要
铁转运障碍是慢性肾脏病(CKD)患者难治性贫血的常见原因.铁调素是机体维持铁稳态的关键激素,可负向调节铁代谢,该过程由多种信号通路调节,包括骨形志发生蛋白/Smad信号通路、Janus激酶/信号转导与转录激活子 3 通路、炎症、促红细胞生成、缺氧等.铁调素已成为临床治疗铁代谢失衡的主要靶点.近年来,国内外研发了多种铁调素调节相关药物,其中以罗沙司他为代表的缺氧诱导因子脯氨酸羟化酶抑制剂类药物被认为可有效减少铁调素表达,提高血清铁水平,进而促进红细胞生成,治疗CKD患者的贫血.
Abstract
Iron transport disorder is a common cause of refractory anemia in chronic kidney disease(CKD)patients.Hepcidin is a key hormone for the body to maintain iron homeostasis,and it can regulate iron metabolism into the negative direction.This feedback regulation process is regulated by multiple pathways,including bone morphogenetic protein(BMP)/Smad signaling pathway,Janus kinase(JAK)/signal transducer and activator of transcription 3(STAT3)pathway,inflammation,erythropoiesis,hypoxia,etc.Hepcidin is the main target for the treatment of iron metabolism imbalance in clinical practice.In recent years,a variety of hepcidin regulation-related drugs have appeared oriented and abroad.Among them,hypoxia-inducible factor prolyl hydroxylase inhibitors(HIF-PHI)drugs such as Roxadustat are believed to effectively reduce the expression of hepcidin,increase serum iron levels,promote iron utilization,and promote red blood cell production to treat anemia in CKD patients.
关键词
铁调素/铁代谢/缺氧诱导因子脯氨酸羟化酶抑制剂/罗沙司他Key words
hepcidin/iron metabolism/hypoxia-inducible factor prolyl hydroxylase inhibitors/Roxadustat引用本文复制引用
基金项目
国家自然科学基金(81570612)
国家自然科学基金(81870497)
江苏省重点研发计划-社会发展(BE2021737)
出版年
2024
NETL
NSTL
万方数据